Why the study?
Does permanent inhibition of guanylyl cyclase A receptor (GC-A) affect cardiac function and hypertrophy in mice?
Does permanent inhibition of guanylyl cyclase A receptor (GC-A) affect cardiac function and hypertrophy in mice?
Chronic hypertension resulting from GC-A deficiency in mice leads to progressive cardiac hypertrophy, interstitial fibrosis, and impaired contractility over time.
Answers are grounded in this paper and cite their sources.
GC-A deficiency induces hypertrophy and dysfunction in mice; leaves open whether GC-A modulation affects human HF progression.
OBJECTIVE: To investigate how permanent inhibition of guanylyl cyclase A receptor (GC-A) affects cardiac function. METHODS: Hearts of GC-A-/- and corresponding wild type mice (GC-A+/+) were characterised by histological, western blotting, and northern blotting analyses. Cardiac function was evaluated in isolated, working heart preparations. RESULTS: At 4 months of age, GC-A-/- mice had global cardiac hypertrophy (about a 40% increase in cardiac weight) without interstitial fibrosis. Examination of heart function found a significant delay in the time of relaxation; all other parameters of cardiac contractility were similar to those in wild type mice. At 12 months, the hypertrophic changes were much more severe (about a 61% increase in cardiac weight), together with a shift in cardiac gene expression (enhanced concentrations of atrial natriuretic peptide (3.8-fold), B type natriuretic peptide (2-fold), beta myosin heavy chain (1.6-fold) and alpha skeletal actin (1.7-fold) mRNA), increased expression of cytoskeletal tubulin and desmin (by 29.6% and 25.6%, respectively), and pronounced interstitial fibrosis. These changes were associated with significantly impaired cardiac contractility (+dP/dt decreased by about 10%) and relaxation (-dP/dt decreased by 21%), as well as depressed contractile responses to pressure load (all p < 0.05). CONCLUSIONS: Chronic hypertension in GC-A-/- mice is associated with progressive cardiac changes--namely, initially compensated cardiomyocyte hypertrophy, which is complicated by interstitial fibrosis and impaired cardiac contractility at later stages.
No takes yet. Share an insight, caveat, or question.
Michaela Kühn (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: